Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
1.140
+0.040 (+3.64%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
40,071
Open
1.100
Bid (Size)
1.050 (10)
Ask (Size)
1.200 (10)
Prev. Close
1.100
Today's Range
1.080 - 1.200
52wk Range
0.6105 - 6.900
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery
September 26, 2023
Via
Investor Brand Network
Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study
September 25, 2023
Via
Investor Brand Network
Performance
YTD
-57.14%
-57.14%
1 Month
-33.33%
-33.33%
3 Month
-48.88%
-48.88%
6 Month
+16.33%
+16.33%
1 Year
-78.77%
-78.77%
More News
Read More
Nottingham University Researchers Find Way to Make Brain Cancer Cells Self-Destruct
September 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients
September 15, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
Via
ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
August 14, 2023
Via
ACCESSWIRE
Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments
September 14, 2023
Via
Investor Brand Network
Study Shares Insights on Why Brain Tumors Are Unresponsive to Immunotherapy
September 11, 2023
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study
September 08, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study
September 07, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
September 07, 2023
Via
ACCESSWIRE
Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas
September 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
September 05, 2023
Via
Investor Brand Network
AI Helps Forecast Brain Tumor Outcomes
August 29, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Canadian Researchers Design Powerful Imaging Tech to Boost Cancer Fight
August 23, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 22, 2023
Via
Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
August 21, 2023
Via
Benzinga
Researchers Develop Novel Way to Detect Pediatric Brain-Cancer Mutations
August 17, 2023
Via
Investor Brand Network
How Healthcare eCommerce Impacts Traditional Providers of Healthcare
August 14, 2023
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin
August 14, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
August 14, 2023
Via
ACCESSWIRE
Israeli Company Seeks to Develop Micro-Robots to Boost Precision Medicine
August 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
August 07, 2023
Via
Investor Brand Network
Exposures
COVID-19
CNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!
August 07, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.